Neumora Therapeutics Q3 EPS $(1.14) Down From $(1.06) YoY; $519.5M In Cash, Cash Equivalents And Marketable Securities Expected To Provide Cash Runway Into 2026
Portfolio Pulse from Benzinga Newsdesk
Neumora Therapeutics reported Q3 losses of $(1.14) per share, a 7.55% decrease YoY. The company has $519.5M in cash, cash equivalents, and marketable securities, expected to provide a cash runway into 2026.
November 01, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neumora Therapeutics reported a YoY decrease in Q3 losses. However, the company has a strong cash position, which is expected to last until 2026.
The increase in losses YoY could negatively impact the stock price in the short term. However, the company's strong cash position could provide some stability and investor confidence in the longer term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100